Identification of genes conferring resistance to 5-fluorouracil

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 31, 2009, Pages 12938-12943

  Byoung, Kwon Yoo ^a   Gredler, Rachel ^a   Vozhilla, Nicollaq ^a   Su, Zao Zhong ^a   Chen, Dong ^a   Forcier, Talitha ^c   Shah, Khalid ^c   Saxena, Utsav ^d   Hansen, Ulla ^d   Fisher, Paul B ^a,b   Sarkar, Devanand ^a,b,e  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Boston University   (United States)

^e NONE   (United States)

Author keywords

5 FU; AEG 1; Chemoresistance; DPYD; LSF

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR LSF; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; CELL ADHESION MOLECULE; DNA; DNA BINDING PROTEIN; KI 67 ANTIGEN; MTDH PROTEIN, HUMAN; TFCP2 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE ELEVATED GENE 1; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CATALYSIS; CONTROLLED STUDY; DRUG METABOLISM; DRUG RESISTANCE; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE REPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LENTIVIRINAE; LIVER CELL CARCINOMA; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GENE; XENOTRANSPLANTATION; ANIMAL; DRUG ANTAGONISM; GENETICS; LIVER TUMOR; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

LENTIVIRUS; MUS MUSCULUS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, HEPATOCELLULAR; CELL ADHESION MOLECULES; CELL LINE, TUMOR; DIHYDROURACIL DEHYDROGENASE (NADP); DNA; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FLUOROURACIL; HUMANS; KI-67 ANTIGEN; LIVER NEOPLASMS; MICE; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTORS;

EID: 69149099584     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0901451106     Document Type: Article

References (51)

1. El-Serag HB, Rudolph KL (2007) Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. Gastroenterology 132:2557-2576.
2. Pang RW, et al. (2008) Biology of hepatocellular carcinoma. Ann Surg Oncol 15:962-971.
3. Llovet JM, Bru C, Bruix J (1999) Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 19:329-338.
4. O'Neil BH, VenookAP(2007) Hepatocellular carcinoma: The role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy. Oncologist 12:1425-1432.
5. Georgiades CS, Hong K, Geschwind JF (2008) Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J 14:117-122.
6. Yeo W, et al. (2005) A randomized phase III study of doxorubicin versus cisplatin/ interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97:1532-1538.
7. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37:429-442.
8. Llovet JM, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 359:1734-1739.
9. Nerenstone S, Friedman M (1987) Medical treatment of hepatocellular carcinoma. Gastroenterol Clin North Am 16:603-612.
10. Leung TW, et al. (1999) Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 5:1676-1681.
11. Patt YZ, et al. (1999) Durable clinical and pathologic response of hepatocellular carcinoma to systemic and hepatic arterial administration of platinol, recombinant interferon alpha 2B, doxorubicin, and 5-fluorouracil: A communication. Am J Clin Oncol 22:209-213.
12. Abou-Alfa GK, et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300.
13. Simpson D, Keating GM (2008) Sorafenib: In hepatocellular carcinoma. Drugs 68:251-258.
14. Zhu AX, et al. (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:1898-1903.
15. Su ZZ, et al. (2002) Identification and cloning of human astrocyte genes displaying elevated expression after infection with HIV-1 or exposure to HIV-1 envelope glycoprotein by rapid subtraction hybridization, RaSH. Oncogene 21:3592-3602.
16. Kang DC, et al. (2005) Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene 353:8-15.
17. Kikuno N, et al. (2007) Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity. Oncogene 26:7647-7655.
18. Sarkar D, et al. (2008) Molecular basis of nuclear factor-kappaB activation by astrocyte elevated gene-1. Cancer Res 68:1478-1484.
19. Emdad L, et al. (2007) Astrocyte elevated gene-1: Recent insights into a novel gene involved in tumor progression, metastasis and neurodegeneration. Pharmacol Ther 114:155-170.
20. Brown DM, Ruoslahti E (2004) Metadherin, a cell surface protein in breast tumors that mediates lung metastasis. Cancer cell 5:365-374.
21. Li J, et al. (2008) Astrocyte elevated gene-1 is a novel prognostic marker for breast cancer progression and overall patient survival. Clin Cancer Res 14:3319-3326.
22. Yoo BK, et al. (2009) Astrocyte elevated gene 1 regulates hepatocellular carcinoma development and progression. J Clin Invest 119:465-477.
23. Kim CH, Heath C, Bertuch A, HansenU(1987) Specific stimulation of simian virus 40 late transcription in vitro by a cellular factor binding the simian virus 40 21-base-pair repeat promoter element. Proc Natl Acad Sci USA 84:6025-6029.
24. Veljkovic J, Hansen U (2004) Lineage-specific and ubiquitous biological roles of the mammalian transcription factor LSF. Gene 343:23-40.
25. Lim LC, Swendeman SL, Sheffery M (1992) Molecular cloning of the alpha-globin transcription factor CP2. Mol Cell Biol 12:828-835.
26. Jones KA, Luciw PA, Duchange N (1988) Structural arrangements of transcription control domains within the 5′-untranslated leader regions of the HIV-1 and HIV-2 promoters. Genes Dev 2:1101-1114.
27. Wu FK, Garcia JA, Harrich D, Gaynor RB (1988) Purification of the human immunodeficiency virus type 1 enhancer and TAR binding proteins EBP-1 and UBP-1. EMBO J 7:2117-2130.
28. Kim CG, Barnhart KM, ShefferyM(1988) Purification of multiple erythroid cell proteins that bind the promoter of the alpha-globin gene. Mol Cell Biol 8:4270-4281.
29. Huang JH, Liao WS (1994) Induction of the mouse serum amyloid A3 gene by cytokines requires both C/EBP family proteins and a novel constitutive nuclear factor. Mol Cell Biol 14:4475-4484.
30. Powell CM, Rudge TL, Zhu Q, Johnson LF, HansenU(2000) Inhibition of the mammalian transcription factor LSF induces S-phase-dependent apoptosis by downregulating thymidylate synthase expression. EMBO J 19:4665-4675.
31. Casolaro V, et al. (2000) Identification and characterization of a critical CP2-binding element in the human interleukin-4 promoter. J Biol Chem 275:36605-36611.
32. Murata T, Nitta M, Yasuda K (1998) Transcription factor CP2 is essential for lens-specific expression of the chicken alphaA-crystallin gene. Genes Cells 3:443-457.
33. Zheng JB, Zhou YH, Maity T, Liao WS, Saunders GF (2001) Activation of the human PAX6 gene through the exon 1 enhancer by transcription factors SEF and Sp1. Nucleic Acids Res 29:4070-4078.
34. Sundseth R, Hansen U (1992) Activation of RNA polymerase II transcription by the specific DNA-binding protein LSF. Increased rate of binding of the basal promoter factor TFIIB. J Biol Chem 267:7845-7855.
35. Romerio F, Gabriel MN, Margolis DM (1997) Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF. J Virol 71:9375-9382.
36. Lopez PM, Villanueva A, Llovet JM (2006) Systematic review: Evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23:1535-1547.
37. Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: Mechanisms of action and clinical strategies. Nature Rev 3:330-338.
38. Yoshinare K, et al. (2003) Gene expression in colorectal cancer and in vitro chemosensitivity to 5-fluorouracil: a study of 88 surgical specimens. Cancer Sci 94:633-638.
39. Oguri T, et al. (2005) The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells. Lung Cancer 49:345-351.
40. Shirra MK, Zhu Q, Huang HC, Pallas D, Hansen U (1994) One exon of the human LSF gene includes conserved regions involved in novel DNA-binding and dimerization motifs. Mol Cell Biol 14:5076-5087.
41. Emdad L, et al. (2006) Activation of the nuclear factor kappaB pathway by astrocyte elevated gene-1: Implications for tumor progression and metastasis. Cancer Res 66:1509-1516.
42. Lee SG, et al. (2008) Astrocyte elevated gene-1 activates cell survival pathways through PI3K-Akt signaling. Oncogene 27:1114-1121.
43. Lee SG, Su ZZ, Emdad L, Sarkar D, Fisher PB (2006) Astrocyte elevated gene-1 (AEG-1) is a target gene of oncogenic Ha-ras requiring phosphatidylinositol 3-kinase and c-Myc. Proc Natl Acad Sci USA 103:17390-17395.
44. van Kuilenburg AB (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40:939-950.
45. Maring JG, et al. (2002) Reduced 5-FU clearance in a patient with low DPD activity due to heterozygosity for a mutant allele of the DPYD gene. Br J Cancer 86:1028-1033.
46. Diasio RB, Beavers TL, Carpenter JT (1988) Familial deficiency of dihydropyrimidine dehydrogenase. Biochemical basis for familial pyrimidinemia and severe 5-fluorouracil-induced toxicity. J Clin Invest 81:47-51.
47. Jiang W, Lu Z, He Y, Diasio RB (1997) Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: Implication in 5-fluorouracil-based chemotherapy. Clin Cancer Res 3:395-399.
48. Johnston SJ, Ridge SA, Cassidy J, McLeod HL (1999) Regulation of dihydropyrimidine dehydrogenase in colorectal cancer. Clin Cancer Res 5:2566-2570.
49. Takahashi T, et al. (2007) Profiling of fluorouracil-related genes by microdissection technique in hepatocellular carcinoma. Hepatogastroenterology 54:1612-1616.
50. Ukon K, et al. (2005) Activator protein accelerates dihydropyrimidine dehydrogenase gene transcription in cancer cells. Cancer Res 65:1055-1062.
51. Kock N, Kasmieh R, Weissleder R, Shah K (2007) Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia 9(5):435-442.